Summary
CVS Health Corporation (CVS) filed an 8-K on August 28, 2019, disclosing a performance stock unit (PSU) award granted to its CEO, Larry J. Merlo, effective August 28, 2019. This grant is intended to align Mr. Merlo's incentives with the successful integration of Aetna and the initial phase of the company's healthcare transformation initiatives. The PSU award, with a target value of $10,125,000, replaces his expected 2020 PSU award and is contingent upon achieving specific performance metrics, including Earnings Per Share growth, de-levering, and relative Total Shareholder Return, with targets consistent with previously provided guidance. The performance measurement period extends through December 31, 2021, aligning with other 2019 performance awards. The award includes provisions for vesting under specific separation circumstances such as separation without cause or qualified retirement. This disclosure is important for investors as it sheds light on executive compensation strategy and its direct link to key strategic objectives and financial performance targets for the company's leadership.
Key Highlights
- 1CVS Health granted a 2020 performance stock unit (PSU) award to CEO Larry J. Merlo, effective August 28, 2019.
- 2The PSU grant replaces Mr. Merlo's planned 2020 PSU award.
- 3The award's value is set at a target of $10,125,000, representing the target value of his 2019 PSU award.
- 4Performance metrics include Earnings Per Share (EPS) growth, de-levering, and relative Total Shareholder Return.
- 5Performance targets for EPS growth and de-levering are consistent with guidance provided at the June 2019 Investor Day.
- 6The performance period for the award runs through December 31, 2021.
- 7The award includes provisions for vesting upon separation without cause and pro-rated vesting upon qualified retirement.